Literature DB >> 2449069

S-100 protein expression by primary and metastatic adenocarcinomas.

G A Herrera1, E A Turbat-Herrera, R L Lott.   

Abstract

S-100 protein has been used as a marker of various lesions, including peripheral nerve sheath, cartilaginous and salivary gland tumors, chordomas, histiocytosis X, and melanomas, among others. The list of neoplasms that can express S-100 protein continues to expand. It has been suggested that staining for S-100 protein may be of aid in the differential diagnosis of amelanotic melanoma versus poorly differentiated tumors. Three hundred fifty primary and metastatic adenocarcinomas from various sites were immunostained for S-100 protein with the use of a commercially available polyclonal antibody. Forty-two percent of the adenocarcinomas tested expressed S-100 protein to varying degrees. The relative incidence of S-100-positive tumors varied with the primary sites, some expressing S-100 protein more often than others. A primary neoplasm able to express S-100 protein was usually associated with metastatic foci also expressing this marker. However, occasionally, a primary S-100-positive tumor was associated with metastasis that lacked expression of S-100. This study emphasizes the importance of testing for a panel of tumor markers in the evaluation of poorly differentiated tumors and cautions on possible difficulties that may arise in the interpretation of immunocytochemistry results.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449069     DOI: 10.1093/ajcp/89.2.168

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  Immunohistochemical characterization of epithelial cells in human lacrimal glands. I. Normal major and accessory lacrimal glands.

Authors:  N Vigneswaran; C M Wilk; A Heese; O P Hornstein; G O Naumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

2.  Immunohistochemical characterization of epithelial cells in human lacrimal glands. II. Inflammatory and neoplastic lesions of lacrimal glands.

Authors:  C M Wilk; N Vigneswaran; A Heese; O P Hornstein; G O Naumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

3.  Microphthalmia transcription factor. A sensitive and specific melanocyte marker for MelanomaDiagnosis.

Authors:  R King; K N Weilbaecher; G McGill; E Cooley; M Mihm; D E Fisher
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

4.  An immunohistochemical and prognostic analysis of cytokeratin expression in malignant uveal melanoma.

Authors:  U Fuchs; T Kivelä; P Summanen; I Immonen; A Tarkkanen
Journal:  Am J Pathol       Date:  1992-07       Impact factor: 4.307

5.  Production and characterisation of an antimelanoma monoclonal antibody KBA.62 using a new melanoma cell line reactive on paraffin wax embedded sections.

Authors:  E Cohen-Knafo; T al Saati; J Aziza; E Ralfkiaer; J Selves; B Gorguet; G Delsol
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

Review 6.  2018 consensus statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the diagnosis and treatment of cancer of unknown primary.

Authors:  F Losa; L Iglesias; M Pané; J Sanz; B Nieto; V Fusté; L de la Cruz-Merino; Á Concha; C Balañá; X Matías-Guiu
Journal:  Clin Transl Oncol       Date:  2018-05-28       Impact factor: 3.405

Review 7.  An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.

Authors:  Andrew M Bellizzi
Journal:  Adv Anat Pathol       Date:  2020-05       Impact factor: 4.571

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.